Farmak, the leader of the pharmaceutical market in Ukraine, has expanded its export geography: in the first half of 2025, China, Sudan, Qatar, and Oman joined the list of export destinations.
Farmak exports a wide range of medicines, including anesthetics, contrast agents for MRI (magnetic resonance imaging), hormonal and cardiological drugs, ophthalmic and anti-allergy products, as well as medicines affecting the digestive system and metabolism, among others.
Today, the company’s products are supplied to more than 60 countries worldwide*. These include the United Kingdom, the UAE, Vietnam, Poland, Pakistan, Jordan, Uzbekistan, Kazakhstan, Australia, and many others.
The company’s production sites and quality control laboratories are certified according to European GMP (Good Manufacturing Practice) standards. This enables exports to countries with the highest regulatory requirements. Each year, Farmak’s R&D complex develops and launches around 20 new medicines, continuously expanding its product portfolio.
In 2024, the Farmak Group acquired the British company group A&S Pharma Holdings Ltd, as well as the marketing company Symphar in Poland.
Today, Farmak Group is a global pharmaceutical business founded in Ukraine in 1925. The Group has manufacturing facilities in Ukraine and Spain, as well as international offices and companies in 11 countries worldwide.
*Refers to exports carried out in 2020–2025.
